Rani Therapeutics
RANI
32 hedge funds and large institutions have $30.4M invested in Rani Therapeutics in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 2 closing their positions.
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
14% more funds holding
Funds holding: 28 → 32 (+4)
13% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 8
1.43% more ownership
Funds ownership: 11.54% → 12.96% (+1.4%)
5% more capital invested
Capital invested by funds: $29.1M → $30.4M (+$1.31M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.37M |
| 2 |
M
MOTCO
San Antonio,
Texas
|
+$510K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$223K |
| 4 |
LI
Lafayette Investments
Ashton,
Maryland
|
+$211K |
| 5 |
ISB
Iowa State Bank
Urbandale,
Iowa
|
+$200K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TWA
TPB Wealth Advisors
San Antonio,
Texas
|
-$251K |
| 2 |
Millennium Management
New York
|
-$240K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
-$196K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$132K |
| 5 |
Goldman Sachs
New York
|
-$111K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Citigroup
New York
| $3K | -$869 | -82 | -22% |
|
27
Simplex Trading
Chicago,
Illinois
| $2K | +$2.35K | +222 | New |
|
|
CUAMC
28
China Universal Asset Management Company
Shanghai,
China
| $2K | +$2.43K | +229 | New |
|
29
BNP Paribas Financial Markets
Paris,
France
| $1.45K | +$1.6K | +151 | New |
|
|
30
Wells Fargo
San Francisco,
California
| $1K | -$132K | -12,462 | -99% |
|
31
Daiwa Securities Group
Tokyo,
Japan
| $1K | – | – | – |
|
32
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | +$657 | +62 | +230% |
|
|
33
Osaic Holdings
Scottsdale,
Arizona
| – | -$196K | -19,012 | Closed |
|
|
34
Goldman Sachs
New York
| – | -$111K | -10,739 | Closed |
|
RANI Hedge Fund Activity: Q3 2022 in Review
32 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Rani Therapeutics (RANI) for Q3 2022, worth a combined $30.4M — up 4.5% from $29.1M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new RANI positions and 2 closed out — a net gain of 5 holders — while 9 added to existing stakes and 8 trimmed.
The largest buyer was Vanguard Group, adding an estimated $3.37M. The largest seller was TPB Wealth Advisors, cutting an estimated $251K.
- 32 institutional investors held Rani Therapeutics (RANI) as of Q3 2022, up from 28 in Q2 2022.
- Funds reported $30.4M of Rani Therapeutics stock for Q3 2022, up 4.5% quarter-over-quarter.
- 7 funds opened new Rani Therapeutics positions in Q3 2022 and 2 closed out, a net change of +5 holders.
- The largest Rani Therapeutics buyer in Q3 2022 was Vanguard Group, an estimated $3.37M added.
- The largest Rani Therapeutics seller in Q3 2022 was TPB Wealth Advisors, an estimated $251K sold.
Based on aggregated 13F filings for Q3 2022.